July 2026RiverVest Mourns Passing of Bradley T. Keller, PhD,Former RiverVest Entrepreneur-in-Residence Bradley T. Keller, PhDMarch 22, 1954 - July 30, 2026In MemoriamWith great sadness, RiverVest mourns the passing of Brad Keller, a longtime friend and colleague who served as a RiverVest entrepreneur-in-residence from 2013 to 2018....
RIVERVEST NEWSLETTERJune 2026 Issue RiverVest invites you to read our latest newsletter, featuring:Portfolio Company Avalyn Pharma Completes Upsized $345 Million IPO 2026 Annual Meeting RecapAtalanta Therapeutics: Reaching the Unreachable in Huntington's Disease...
/ EXPERT INSIGHTSAtalanta Therapeutics: Reaching the Unreachable in Huntington's Disease by Pascal Krotee, PhDRiverVest PrincipalThe promise of broad and durable gene silencing using RNA interference(May 15, 2026) Huntington’s disease (HD) has long stood as one of the most challenging neurodegenerative disorders to address therapeutically. Despite a...
RIVERVEST NEWSLETTERFebruary 2026 Issue RiverVest invites you to read our latest newsletter, featuring:Portfolio Company Bluejay Therapeutics Acquired by Mirum PharmaceuticalsJPM 2026 Recap: Signals are Getting ClearerRiverVest Scientific Advisor Alessandro Sette to Receive Prestigious Immunology AwardCould Excess Cortisol...
/ EXPERT INSIGHTSJPM 2026 Recap: Signals Are Getting Clearer by Isaac Zike, PhDManaging Director of RiverVestVenture PartnersThis year's conference was familiar in tone, strengthened by substance(February 10, 2026) – Niall O'Donnell and I joined thousands of global pharmaceutical and biotech leaders, innovators, and investors in San...
RiverVest Year in Review: 2025...
DECEMBER 2025Portfolio Company Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals ST. LOUIS--(December 8, 2025)-- Bluejay Therapeutics – a RiverVest Venture Fund V portfolio company – has entered into a definitive agreement to be acquired by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a former RiverVest portfolio company focusing...
Nicklaus: With $115 Million in Hand, Biotech Startup Eyes the Finish Line...
/ EXPERT INSIGHTSCould Excess Cortisol Be Driving Type 2 Diabetes Resistance? by Niall O'Donnell, PhDManaging Director of RiverVestVenture PartnersWhy taming a stress hormone might be the next breakthrough in type 2 diabetes care(September 24, 2025) - Millions of people on type 2 diabetes (T2B) regimens do...
August 2025RiverVest Mourns Passing of Ronald T. Borchardt, PhD,RiverVest Scientific Advisory Board Member Ronald T. Borchardt, PhDFebruary 18, 1944 - July 15, 2025In MemoriamWith great sadness, RiverVest mourns the passing of Dr. Ronald T. Borchardt, a valued member of our scientific advisory board since 2015. Ron’s...
Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility? ...
RIVERVEST NEWSLETTERJune 2025 Issue RiverVest invites you to read our latest newsletter, featuring:2025 Annual Meeting RecapRiverVest Portfolio: Year in ReviewThe Sugar Fix: A New Approach to Treating a Rare Glycosylation DisorderPortfolio NewsRiverVest News features insights and updates on...
Learn how Alleviant's no-implant approach addresses the full spectrum of chronic heart failure....
RiverVest Year in Review: 2024...
ST. LOUIS (December 12, 2024)—RiverVest Venture Partners, a leading life science venture capital firm, today announced that John C. Cambier, Ph.D., and Gary De Crescenzo have joined the firm’s Scientific Advisory Board. Composed of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance...
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....